OncoMatch/Clinical Trials/NCT05952934
Candida Therapeutic Vaccine in Head and Neck Cancer Patients to Reduce Recurrence
Is NCT05952934 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies 0.5 mL Candin®/injection for squamous cell carcinoma of head and neck.
Treatment: 0.5 mL Candin®/injection — This is a Phase II randomized, double-blind, placebo controlled, multi-site study of Candin. It is designed to show the efficacy and safety of a 7-dose regimen of Candin over a two-year period in terms of reducing cancer recurrence rate by comparing the recurrence rates between the Candin and the placebo arm. The ratio of the number of subjects who will receive Candin versus placebo will be 3:1. Up to 100 subjects will be screened until 80 subjects are eligible for injection.
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Prior therapy
Must have received: curative therapy
completed curative therapy (surgery and/or radiation and/or chemotherapy) within the previous 120 days
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Highlands Oncology Group, PA · Fayetteville, Arkansas
- University of Arkansas for Medical Sciences · Little Rock, Arkansas
- Highlands Oncology Group, PA · Rogers, Arkansas
- Highlands Oncology Group, PA · Springdale, Arkansas
- Perlmutter Cancer Center at NYU Langone Health · Mineola, New York
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify